



ANDA 65-259

Food and Drug Administration
Rockville MD 20857

MAY 31 2006

Lupin Pharmaceuticals Inc.
Attention: Vinita Gupta
U.S. Agent for: Lupin Limited
Harborplace Tower
111 South Calvert Street
21st Floor
Baltimore, MD 21202

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated September 24, 2004, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Cefdinir for Oral Suspension, 125 mg/5 mL. We note that this product is subject to the exception provisions of section 125(d)(2) of Title I of the Food and Drug Administration Modernization Act of 1997.

Reference is also made to your amendments dated January 27, July 15, August 23, and October 28, 2005.

We have completed the review of this ANDA and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved. The Division of Bioequivalence has determined your Cefdinir for Oral Suspension, 125 mg/5 mL to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Omnicef® for Oral Suspension, 125 mg/5 mL, of Abbott Laboratories). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Amundson Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications (HFD-42) with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,



Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research